11Dec 2024
Brolucizumab Matches Aflibercept for DME

Brolucizumab Matches Aflibercept for DME

The study analyzed data from 1253 patients across three RCTs comparing brolucizumab and aflibercept for diabetic macular edema (DME). Brolucizumab showed non-inferior improvements in best-corrected visual acuity (LSMD 0.29; p = 0.73) and significantly greater reductions in central subfield thickness (LSMD −24.5 μm; p < 0.05). Adverse event rates, including AESIs (RR 1.7; p = 0.08) and ocular AEs (RR 0.95; p = 0.45), were not significantly different between treatments. Results suggest brolucizumab as a promising alternative, though further RCTs are needed to confirm safety.

  • #ophthalmology
  • #endo-diabetology

Like

Save

Share